Morganti, Stefania
Parsons, Heather A.
Lin, Nancy U.
Grinshpun, Albert http://orcid.org/0000-0002-3351-5719
Funding for this research was provided by:
Conquer Cancer - Israel Cancer Research Fund Career Development Award
Associazione Italiana per la Ricerca sul Cancro
Fondazione Bonadonna
Article History
Received: 7 March 2023
Accepted: 12 May 2023
First Online: 24 May 2023
Competing interests
: H.A.P. reports research funding from Puma Biotechnology (paid to institution) and advisory roles at Illumina, Caris and SAGA Diagnostics. N.U.L. reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca; consulting honoraria from Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines; stock and other ownership interests in Artera Inc. (<$50k and <5% as it relates to consulting activities – options are not currently valued or in-hand); and royalties from Up to Date (book). The remaining authors declare no competing interests.